Curcumin

Curcumin (C8069) is found in turmeric, a plant of the ginger family. Turmeric has traditionally been used to dye clothing and to preserve food. Along with curcumin, the two other primary curcuminoids present in turmeric are Demethoxycurcumin (D1850) and Bisdemethoxycurcumin (B3573). These three compounds exhibit antioxidative, anticancer, anti-inflammatory, and antimicrobial properties.

Curcumin displays antiviral activity, inhibiting HIV-1 integrase activity in vitro¹. HIV integrase is a key regulator of the retroviral life cycle. Additionally, curcumin inhibits HIV-1 replication².

Curcumin also exhibits neuroprotective activity. This compound prevents formation of soluble oligomers in amyloid- β -infused animal models³. Aggregation of amyloid- β (A β) fibrils into plaques is a key process in the progression of Alzheimer's disease. Curcumin accumulates near amyloid deposits in vivo; it also prevents the formation of new A β plaques and clears existing aggregations⁴.

In cellular models of breast cancer, curcumin decreases metastatic activity. In this study, curcumin prevents transcription of CXCL1 and CXCL2, silencing activity of CXCR4 and other metastasis-promoting proteins⁵.

Other studies highlight a different role for curcumin in cancer models. In one study, curcumin promotes the progression of lung lesions from benign hyperplasias to adenomas and carcinomas.



Available curcuminoids:
C8069 Curcumin
C8070 Curcumin (high purity)
D1850 Demethoxycurcumin
B3573 Bisdemethoxycurcumin
D3449 Dimethoxycurcumin
D3420 3,4-Difluorobenzocurcumin

When compared to BHT, a known carcinogen, administration of curcumin induces a similar increase in tumor growth and progression. This carcinogenic potential may be linked to modulation of ROS levels and oxidative stress in lung tissue⁶. This compound also disrupts the natural conformation of tumor suppressor p53, inhibiting its ability to bind DNA and induce cell cycle arrest⁷.

In addition to curcumin, LKT Laboratories carries several other curcuminoids, including **3,4-Difluoro-benzocurcumin** (**D3420**). This compound is in early stages of research but shows potential activity in a variety of biological applications as it exhibits better pharmacokinetic bioavailability and stronger pharmacological activity than curcumin⁸.

References:

- 1. Ferreira VH, Nazli A, Dizzell SE, et al. PLoS One. 2015 Apr 9;10(4):e0124903.
- 2. Artico M, Di Santo R, Costi R, et al. J Med Chem. 1998 Oct 8;41(21):3948-60.
- 3. Kochi A, Lee HJ, Vithanarachchi SM, et al. Curr Alzheimer Res. 2015;12(5):415-23.
- 4. Garcia-Alloze M, Borrelli A, Rozkalne A, et al. J Neurochem. 2007 Aug;102(4):1095-104.
- 5. Bachmeier B, Mohrenz I, Mirisola V, et al. Carcinogenesis. 2008 Apr;29(4):779-89.
- 6. Dance-Barnes S, Kock N, Moore J, et al. Carcinogenesis. 2009 Jun;30(6):1016-23.
- 7. Moos P, Edes K, Mullally J, et al. Carcinogenesis. 2004 Sep;25(9):1611-7.
- 8. Ali S, Ahmad A, Banerjee S, et al. Cancer Res. 2010 May 1;70(9):3606-17.







